Invicta Diagnos.

Why is Invicta Diagnostic Ltd falling/rising?

As of 09-Jul, Invicta Diagnostic Ltd's stock price is at 69.40, down 0.79%. Despite a recent weekly increase, the stock has struggled year-to-date, trading below key moving averages, indicating a bearish trend.

As of 09-Jul, Invicta Diagnostic Ltd's stock price is currently at 69.40, reflecting a decrease of 0.55, or 0.79%. This decline can be attributed to its performance today, where it underperformed the sector by 1.96%. Despite a positive trend over the past week, where the stock has risen by 2.06% compared to a decline in the Sensex of 0.88%, the stock is still facing challenges. <BR><BR>While the stock has shown a significant increase of 13.40% over the past month, its year-to-date performance is down by 12.48%, indicating a longer-term struggle. Additionally, the stock is currently trading below its 50-day, 100-day, and 200-day moving averages, which suggests a bearish trend in the medium to long term. <BR><BR>On a more positive note, there has been a rise in investor participation, with delivery volume increasing by 28.21% against the 5-day average, indicating some interest from investors. However, the overall liquidity remains stable, as the stock is liquid enough for trading purposes. <BR><BR>In summary, while there are some positive indicators, the current decline in stock price is primarily influenced by its underperformance today and its position relative to longer-term moving averages.

Which are the latest news on Invicta Diagnos.?

What does Invicta Diagnos. do?

Invicta Diagnostic Ltd is a micro-cap healthcare services company, incorporated in 2021 and converted to a Private Limited Company in December 2023. It currently has no available revenue or profit data, with a market cap of INR 77 Cr and a P/E ratio of 16.00.

Overview:<BR>Invicta Diagnostic Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Invicta Diagnostic Ltd was incorporated in 2021 as a Limited Liability Partnership under the name "Invicta Diagnostic LLP." It converted into a Private Limited Company on December 01, 2023. Revenue and profit data are not available for any reporting period.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 77 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 16.00<BR>Industry P/E: 60<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.37<BR>Return on Equity: 9.84%<BR>Price-to-Book: 1.54<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Invicta Diagnos.?

As of 10th June, Invicta Diagnostic Ltd has a market capitalization of 77.00 Cr, classifying it as a Micro Cap company. There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Invicta Diagnostic Ltd has a market capitalization of 77.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 16.83 Cr and Total Assets totaling 21.25 Cr.

Who are the peers of the Invicta Diagnos.?

Invicta Diagnos.'s peers include Aakaar Medical, Choksi Laborator, Royal Sense, and others, with varying management risks and growth rates. Royal Sense shows the highest 1-year return at 0.00%, while several peers have negative six-month returns.

Peers: The peers of Invicta Diagnos. are Aakaar Medical, Choksi Laborator, Royal Sense, Shree Pacetronix, Amkay Products, Aspira Pathlab, Bandaram Pharma, Star Imaging, KMS Medisurgi.<BR><BR>Quality Snapshot: Excellent management risk is observed at Royal Sense and Star Imaging, while Good management risk is found at Aakaar Medical, Shree Pacetronix, Amkay Products, and the rest. Below Average management risk is noted at Choksi Laborator, Aspira Pathlab, Bandaram Pharma, and the rest. Growth is Excellent at Royal Sense, Good at Aakaar Medical, Shree Pacetronix, Bandaram Pharma, and the rest, while Below Average growth is seen at Amkay Products, Aspira Pathlab, and the rest. Capital Structure is Excellent at Star Imaging, Good at Aakaar Medical, Shree Pacetronix, Amkay Products, KMS Medisurgi, and the rest, while Below Average capital structure is found at Choksi Laborator, Bandaram Pharma, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Royal Sense with 0.00%, while the peer with the lowest is Aspira Pathlab, also with 0.00%. Invicta Diagnos.'s 1-year return is not available for comparison. Additionally, Aakaar Medical, Amkay Products, Aspira Pathlab, Bandaram Pharma, Star Imaging, and KMS Medisurgi all have a six-month return that is negative.